NELARABINE-REACH nelarabine 250 mg/50 mL solution for infusion vial

Kraj: Australia

Język: angielski

Źródło: Department of Health (Therapeutic Goods Administration)

Składnik aktywny:

nelarabine, Quantity: 250 mg

Dostępny od:

Reach Pharmaceuticals Pty Ltd

Forma farmaceutyczna:

Injection, solution

Skład:

Excipient Ingredients: sodium chloride; sodium hydroxide; hydrochloric acid; water for injections

Droga podania:

Intravenous Infusion

Sztuk w opakowaniu:

6, 1

Typ recepty:

(S4) Prescription Only Medicine

Wskazania:

Nelarabine is indicated for the treatment of patients with relapsing /refractory T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment.,Due to the small patient populations in these disease settings, the information to support these indications is based on limited data..

Podsumowanie produktu:

Visual Identification: Clear colourless solution.; Container Type: Vial; Container Material: Glass; Container Life Time: 18 Months; Container Temperature: Store below 25 degrees Celsius

Status autoryzacji:

Registered